This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jespersen, D. J.
Right arrow Articles by Cockerill III, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jespersen, D. J.
Right arrow Articles by Cockerill III, F. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, December 2002, p. 4782-4784, Vol. 40, No. 12
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.12.4782-4784.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Comparison of the Borrelia DotBlot G, MarDx, and VIDAS Enzyme Immunoassays for Detecting Immunoglobulin G Antibodies to Borrelia burgdorferi in Human Serum

Deborah J. Jespersen,1 Thomas F. Smith,1 Jon E. Rosenblatt,1,2 and Franklin R. Cockerill III1,2*

Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology,1 Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 559052

Received 1 May 2002/ Returned for modification 4 August 2002/ Accepted 13 September 2002

Three enzyme immunoassays, Borrelia DotBlot G (GenBio, San Diego, Calif.), MarDx EIA (MarDx Diagnostics, Inc., Carlsbad, Calif.), and VIDAS (bioMérieux, St. Louis, Mo.) were compared for their ability to detect immunoglobulin G antibodies to Borrelia burgdorferi in 100 human serum samples. The "gold standard" positive result for each of these samples was determined by Western immunoblot analysis (MarDx Marblot Test System) (n = 99) or clinical signs and symptoms suggestive of Lyme disease with other laboratory results positive for B. burgdorferi (n = 1). Based on these criteria for a gold standard positive result, 29 of the 100 samples tested were considered true positives and 71 were considered true negatives. The following sensitivities and specificities were noted, respectively, for each method: Borrelia DotBlot G, 93 and 90%; MarDx, 100 and 35%; and VIDAS, 100 and 92%. Because of high sensitivity and specificity and ease of use, the VIDAS test is an appealing method, especially for laboratories that perform high volumes of tests. The high sensitivity but low specificity of the MarDx method compared to the VIDAS and Borrelia DotBlot G methods requires that Western blot confirmatory tests be performed frequently. The Borrelia DotBlot G method has acceptable specificity but appears to lack sensitivity when compared to the VIDAS and MarDx methods.


* Corresponding author. Mailing address: Mayo Clinic, 200 First St. SW, Hilton 470, Rochester, MN 55905. Phone: (507) 284-2901. Fax: (507) 284-4272. E-mail: cockerill.franklin{at}mayo.edu.


Journal of Clinical Microbiology, December 2002, p. 4782-4784, Vol. 40, No. 12
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.12.4782-4784.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Lakos, A., Ferenczi, E., Komoly, S., Granstrom, M. (2005). Different B-cell populations are responsible for the peripheral and intrathecal antibody production in neuroborreliosis. Int Immunol 17: 1631-1637 [Abstract] [Full Text]  
  • Jobe, D. A., Lovrich, S. D., Schell, R. F., Callister, S. M. (2003). C-Terminal Region of Outer Surface Protein C Binds Borreliacidal Antibodies in Sera from Patients with Lyme Disease. CVI 10: 573-578 [Abstract] [Full Text]